Learn More
The Hemostasis and Thrombosis Research Society Registry was used to monitor the postapproval use and safety of recombinant activated factor VII (rFVIIa). The objective of this article is to evaluate(More)
BACKGROUND Noonan syndrome (NS) is a genetic disorder characterized by phenotypic features, including facial dysmorphology, cardiovascular anomalies, and short stature. Growth hormone (GH) has been(More)
OBJECTIVE To identify factors associated with growth in children on growth hormone (GH) therapy using data from the American Norditropin Studies: Web-enabled Research (ANSWER) Program® registry. (More)
INTRODUCTION Standardized and disease-specific patient-reported outcome (PRO) instruments assessing pain, functional impairment and health-related quality of life (HRQoL) in people with haemophilia(More)
BACKGROUND A primary goal of recombinant human growth hormone therapy (GHT) in children is attaining normal adult height. In this study, children with growth hormone deficiency (GHD) (including(More)
INTRODUCTION Acquired haemophilia (AH) is a rare disorder caused by autoantibodies against factor VIII. AIM The Hemostasis & Thrombosis Research Society (HTRS) Registry was used to monitor the(More)
Control of bleeding in patients with congenital haemophilia with inhibitors requires use of bypassing agents such as recombinant activated factor VII (rFVIIa). Due to the difficulties in performing(More)